From: Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
FACT-M
EQ-5D-5L
Intervention group
Control group
n (%)
Baseline
63 (94)
67 (94)
Week 24
51 (76)
53 (75)
52 (78)
54 (76)
Week 48
38 (56)
35 (49)
39 (58)
36 (51)